Press release
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2034, Growing at a CAGR of 7.44%
Direct Oral Anticoagulants (DOACs) Device Market
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reach 64.83 Billion by 2034. It is anticipated to register a CAGR of 7.44% during the forecast period, 2025 to 2034.
What is Direct Oral Anticoagulants (DOACs) Device?
The Direct Oral Anticoagulants (DOACs) device market is driven by increasing incidences of thromboembolic disorders such as deep vein thrombosis and atrial fibrillation. DOACs, which include drugs like apixaban, rivaroxaban, and dabigatran, offer advantages over traditional anticoagulants such as warfarin, including fewer dietary restrictions, no need for regular INR monitoring, and a predictable pharmacokinetic profile. Devices associated with DOAC delivery, monitoring, and adherence support are experiencing growing demand, especially in aging populations with higher cardiovascular risks. Technological innovations in point-of-care testing and wearable monitoring devices are also contributing to market growth. Additionally, patient preference for oral administration and physician confidence in DOACs' safety and efficacy profiles further boost the market. Regulatory support and increasing awareness about stroke prevention are likely to expand market potential globally. North America and Europe are the leading regions due to established healthcare infrastructure and favorable reimbursement policies.
Download Free Sample PDF Copy of the Report:
https://www.polarismarketresearch.com/industry-analysis/direct-oral-anticoagulants-doacs-device-market/request-for-sample
What Is the Report Scope?
• Provides a comprehensive analysis of the market, including historical data, current trends, and future projections.
• Covers both qualitative and quantitative insights to support strategic decision-making.
• Examines key market segments and sub-segments to offer an in-depth market assessment.
• Includes detailed regional analysis covering major geographic markets.
• Assesses the competitive landscape with profiles of leading players, recent developments, and strategic initiatives.
What's Propelling Market Forward?
Ongoing innovation, rising demand across key sectors, and supportive industry trends are driving the upward trajectory of the Direct Oral Anticoagulants (DOACs) Device market. Below are some of the primary forces fueling this growth:
The Direct Oral Anticoagulants (DOACs) device market is being driven by the increasing prevalence of cardiovascular diseases, including atrial fibrillation and venous thromboembolism, which necessitate long-term anticoagulation therapy. The shift away from traditional warfarin therapy, due to its narrow therapeutic index and need for regular monitoring, has led to a surge in demand for DOACs and associated monitoring devices. Improved patient compliance, reduced risk of food and drug interactions, and fewer bleeding complications have contributed to market adoption. Additionally, technological advancements in point-of-care testing devices for anticoagulant levels and growing awareness among physicians regarding the benefits of DOACs are reinforcing market expansion. Regulatory approvals and inclusion of DOACs in treatment guidelines are also accelerating their use globally. As the aging population continues to rise, so does the burden of chronic conditions that require anticoagulation, further enhancing the need for reliable, convenient DOAC monitoring and management devices.
Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/direct-oral-anticoagulants-doacs-device-market/request-for-discount-pricing
Who Are Market Key Players?
This market features dynamic competition where prominent organizations continuously innovate and pursue strategic alliances to expand their market share and influence. Key Direct Oral Anticoagulants (DOACs) Device market participants include:
• Siemens Healthineers
• Abbott Laboratories
• Roche Diagnostics
• Sysmex Corporation
• Instrumentation Laboratory (Werfen)
• Nihon Kohden Corporation
• Diagnostica Stago
• Coag-Sense
• HemoSonics
• Sekisui Medical Co., Ltd.
• Grifols S.A.
• Helena Laboratories Corporation
Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/direct-oral-anticoagulants-doacs-device-market
Which Region Leads Market Demand?
The global market exhibits varied growth patterns across regions, with certain areas leading due to strong industrial presence, higher investment levels, and favorable economic conditions.
• North America
o US
o Canada
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Netherlands
o Russia
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Malaysia
o South Korea
o Indonesia
o Australia
o Vietnam
o Rest of Asia Pacific
• Middle East & Africa
o Saudi Arabia
o UAE
o Israel
o South Africa
o Rest of Middle East & Africa
• Latin America
o Mexico
o Brazil
o Argentina
o Rest of Latin America
How Is Market Segmentation Done?
The market segmentation section provides a clearer understanding of demand patterns and growth opportunities across different segments. The market is segmented based on the following key parameters:
By Product Type Outlook (Revenue, USD Billion, 2020-2034)
• Factor Xa Inhibitors
• Direct Thrombin Inhibitors
By Disease Indication Outlook (Revenue, USD Billion, 2020-2034)
• Atrial Fibrillation
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Heart Attacks
• Post-Surgical Thromboprophylaxis
• Others
By Application Outlook (Revenue, USD Billion, 2020-2034)
• Stroke Prevention
• Venous Thromboembolism Prevention
• Treatment of Acute Thrombotic Events
• Long-Term Prophylaxis
• Other Application
By Patient Demographic Outlook (Revenue, USD Billion, 2020-2034)
• Pediatric
• Adult
• Geriatric
By End User Outlook (Revenue, USD Billion, 2020-2034)
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Homecare Settings
• Others
Browse More Research Reports:
Direct Oral Anticoagulants (DOACs) Device Market:
https://www.polarismarketresearch.com/industry-analysis/direct-oral-anticoagulants-doacs-device-market
Molecular Diagnostics For Sexually Transmitted Diseases Market:
https://www.polarismarketresearch.com/industry-analysis/molecular-diagnostics-for-sexually-transmitted-diseases-market
Topical Drugs Cdmo Market:
https://www.polarismarketresearch.com/industry-analysis/topical-drugs-cdmo-market
Traumatic Brain Injury Biomarkers Market:
https://www.polarismarketresearch.com/industry-analysis/traumatic-brain-injury-biomarkers-market
Cellulite Treatment Market:
https://www.polarismarketresearch.com/industry-analysis/cellulite-treatment-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2034, Growing at a CAGR of 7.44% here
News-ID: 4102449 • Views: …
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of …
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. It…
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 …
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected to…
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin …
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billion…
Captive Portal Market Projected to Reach USD 6.55 Billion by 2034, Growing at a …
Captive Portal Market
Polaris Market Research has released new insights into the Captive Portal Market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
The global captive portal market size was valued at USD 1.86 billion in 2024, growing at a CAGR of…
More Releases for DOAC
Anticoagulants Market Analysis, Share, Growth, Trends and Report 2026
Anticoagulants Market - Snapshot
Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are among the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and…
Anticoagulants Market is Projected to Expand at a CAGR of 8.0% from 2018 to 2026
The global anticoagulants market is expected to grow at a sturdy pace in the years to follow. An article titled, “Anticoagulant Medications for the Prevention and Treatment of Thromboembolism” was recently published by AACN Advanced Critical Care. The review offers insights to nurses and doctors on the latest developments in the field of thrombolysis and anticoagulation mechanisms.The primary goals behind such reviews involve developing awareness about the possibility of improved…
Venous Thromboembolism (VTE) Market Industry Analysis By Leading Key Players: Pf …
Heparin has been the gold standard for treating VTE. In a recent study published (2017) in the New England Journal of Medicine, Rivaroxaban has shown to be more effective in reducing the risk of recurrent events in patients with venous thromboembolism in equipoise with continued anticoagulation medications compared to Aspirin. Devices used for treating VTE include compression stockings, and intermittent pneumatic compression devices. Thrombolytic therapy includes administering tissue plasminogen activator.
The…
Anticoagulants Market Latest Innovations by Leading Key Players like Bayer Healt …
Anticoagulants Market – Overview
Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial…
Venous Thromboembolism (VTE) Market 2019 Top Key Players: Pfizer Inc., Boehringe …
According to the International Society on Thrombosis and Hemostasis, Inc., venous thromboembolism (VTE) is a leading cause of death and disability worldwide. Approximately 10 million cases of venous thromboembolism occur annually. VTE refers to the formation of blood clots in vein. If the clot is in deep vein (usually leg), it is called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism.
Request for a sample…
Venous Thromboembolism (VTE) Market Opportunity Analysis 2019: Pfizer Inc., Boeh …
According to the International Society on Thrombosis and Hemostasis, Inc., venous thromboembolism (VTE) is a leading cause of death and disability worldwide. Approximately 10 million cases of venous thromboembolism occur annually. VTE refers to the formation of blood clots in vein. If the clot is in deep vein (usually leg), it is called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism.
Request for a sample…
